Biotech · Private company
Acerta Pharma BV
Track this companyFree. Adds Acerta Pharma BV to your Dealase workspace and tells you when its record changes.
Clinical trials2515 recruiting or active
Pipeline programs44From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline44
- acalabrutinibPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 3 · Lymphoma, Mantle CellClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib (ACP-196)Phase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 3 · Lymphoma, Mantle CellClinicalTrials.gov · fetched Nov 12, 2026
- BendamustinePhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ChemoimmunotherapyPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ChlorambucilPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IdelalisibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Lymphoma, Mantle CellClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- VincristinePhase 3 · Diffuse Large B-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- acalabrutinibPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 2 · Follicular Lymphoma (FL)ClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 2 · Non-Hodgkins LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib (ACP-196)Phase 2 · Waldenström Macroglobulinemia (WM)ClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib (Arm A)Phase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib (Arm B)Phase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ACP-196Phase 2 · Glioblastoma MultiformeClinicalTrials.gov · fetched Nov 12, 2026
- ACP-196 (acalabrutinib)Phase 2 · Mantle Cell Lymphoma (MCL)ClinicalTrials.gov · fetched Nov 12, 2026
- ACP-196 (acalabrutinib)Phase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ACP-319Phase 2 · Non-Hodgkins LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- LenalidomidePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Follicular Lymphoma (FL)ClinicalTrials.gov · fetched Nov 12, 2026
- rituximab (IV)Phase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- AcalabrutinibPhase 1 · Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)ClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib in combination with BRPhase 1 · Mantle Cell Lymphoma (MCL)ClinicalTrials.gov · fetched Nov 12, 2026
- Acalabrutinib in combination with VRPhase 1 · Mantle Cell Lymphoma (MCL)ClinicalTrials.gov · fetched Nov 12, 2026
- ACP-319Phase 1 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- AZD5153Phase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- AZD6738Phase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- AZD9150Phase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Hu5F9-G4Phase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
- IsavuconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · NHLClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 8, 2020ClinicalTrials.gov NCT04529772 · fetched Nov 12, 2026
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.PHASE2 · COMPLETED · started Jun 13, 2020ClinicalTrials.gov NCT04380688 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Jan 3, 2020ClinicalTrials.gov NCT05140096 · fetched Nov 12, 2026
- Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLPHASE2 · UNKNOWN · started Aug 16, 2019ClinicalTrials.gov NCT03736616 · fetched Nov 12, 2026
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 25, 2019ClinicalTrials.gov NCT03836261 · fetched Nov 12, 2026
- Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaPHASE2 · COMPLETED · started Nov 29, 2018ClinicalTrials.gov NCT03623373 · fetched Nov 12, 2026
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPHASE2 · RECRUITING · started Sep 10, 2018ClinicalTrials.gov NCT03516617 · fetched Nov 12, 2026
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)PHASE1 · COMPLETED · started Jun 19, 2018ClinicalTrials.gov NCT03527147 · fetched Nov 12, 2026
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 5, 2017ClinicalTrials.gov NCT02972840 · fetched Nov 12, 2026
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 2, 2017ClinicalTrials.gov NCT02970318 · fetched Nov 12, 2026
- A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 20, 2016ClinicalTrials.gov NCT02717624 · fetched Nov 12, 2026
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 8, 2016ClinicalTrials.gov NCT02717611 · fetched Nov 12, 2026
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 25, 2016ClinicalTrials.gov NCT02586857 · fetched Nov 12, 2026
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 28, 2015ClinicalTrials.gov NCT02477696 · fetched Nov 12, 2026
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 26, 2015ClinicalTrials.gov NCT02475681 · fetched Nov 12, 2026
- An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell LymphomaPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 2, 2015ClinicalTrials.gov NCT02213926 · fetched Nov 12, 2026
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesPHASE1_PHASE2 · COMPLETED · started Feb 20, 2015ClinicalTrials.gov NCT02362035 · fetched Nov 12, 2026
- Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLPHASE2 · COMPLETED · started Jan 12, 2015ClinicalTrials.gov NCT02337829 · fetched Nov 12, 2026
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 29, 2014ClinicalTrials.gov NCT02180711 · fetched Nov 12, 2026
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLPHASE1 · COMPLETED · started Dec 22, 2014ClinicalTrials.gov NCT02296918 · fetched Nov 12, 2026
- Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesPHASE1_PHASE2 · COMPLETED · started Dec 20, 2014ClinicalTrials.gov NCT02328014 · fetched Nov 12, 2026
- An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 11, 2014ClinicalTrials.gov NCT02180724 · fetched Nov 12, 2026
- Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 18, 2014ClinicalTrials.gov NCT02157324 · fetched Nov 12, 2026
- Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaPHASE1 · COMPLETED · started Aug 7, 2014ClinicalTrials.gov NCT02112526 · fetched Nov 12, 2026
- ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2014ClinicalTrials.gov NCT02029443 · fetched Nov 12, 2026